Integra LifeSciences (IART) Q3 2026 earnings review
Integra cut its debt, but sales will shrink this quarter
Integra's brain-surgery products sold well, but a flooded plant and weak wound-care sales held the company back. Revenue rose 2% to $411 million, with about $7 million lost because the Cincinnati factory could not ship. Chairman and chief executive Stuart Essig called the results mixed and cut the full-year outlook, since the flood costs more in the fourth quarter and wound-care demand came in softer than he expected. Cash generation was the strongest part of the quarter, and the company refinanced its debt after the quarter ended.
| Revenue | $411.2M +2.3% from a year ago; about $7M lost to the flood |
|---|---|
| Profit per share, excluding one-offs | $0.59 +9% from a year ago |
| Operating cash flow | $96.0M $40.9M a year ago |
| Full-year revenue outlook | Cut $30.5M middle of the range: 0.5% growth |
⚖️ Verdict: 🔴 Bearish
The story got worse because the plan now has sales falling in the fourth quarter and the margin gains promised for this year are gone. The good news: operating cash flow more than doubled, leverage fell to 3.8 times earnings, and October's refinancing pushed the debt deadlines out. One caution: profit per share grew on other income rather than operations, so the cash is the firmer of the two gains.
The question now is whether sales grow again once the Cincinnati plant is back, or whether the wound-care business keeps shrinking regardless. If the fourth-quarter decline is mostly the flood, 2027 starts from a clean base; if Tissue Reconstruction keeps falling, the problem is the products, not the plant. Fourth-quarter Tissue Reconstruction revenue and the full-year outlook in February will tell.
🐂 Bull Case
Neurosurgery Grew 6.5% Despite the Flooded Plant
Specialty Surgery, Integra's division for brain surgery, ear-nose-and-throat and surgical instrument products, is 70% of revenue. Chairman and chief executive Stuart Essig pointed to "stronger performance in Specialty Surgery", even though the flooded Cincinnati plant kept about $7 million of its goods from shipping.
Neurosurgery, the largest line, grew 6.5% before currency effects on CereLink, Certas Plus, Bactiseal, DuraSeal and "recovery in cranial perforators", the company said. Instruments and ENT each slipped about 1%, and the division grew 4.2% in total.
Without the flood the division would have grown about 6.3% by our math, and the presentation credits "Improved product availability and continued demand strength", so the quarter supports the case that supply, not demand, had held it back. Nothing new came on selling wound products through neurosurgery hospital contracts.
What to watch: Neurosurgery growth in the fourth quarter, when the company says the $15–20 million flood hit lands mostly on this line. Growth near zero despite that hit would mean demand held through the disruption.
Operating Cash Flow Rose to $96 Million
Integra carries about $1.5 billion of net debt, so cash generation rather than reported profit decides how fast it can pay lenders down. The company has promised $190–200 million of operating cash flow for 2026 after only $50 million in 2025, and until this quarter most of that total still had to arrive.
- Operating cash flow: $96.0 million in the quarter, against $40.9 million a year ago
- Nine months: $128.6 million, against $38.6 million
- Free cash flow: $85.7 million, or 185% of profit excluding one-offs
- Net debt: $1.52 billion, down $79 million since December
- Leverage: 3.8 times earnings, from 4.5 in December and 4.1 in June
This matters because by our math the full-year plan now needs only $61–71 million in the fourth quarter, less than the company has just produced in one, so the back-loaded cash plan looks reachable. Part of the cash came from collecting receivables and running down inventory, which cannot repeat every quarter; part came from lower one-off charges, which can. None went to buybacks, and financing activities used $38.8 million over nine months, so the money went to the lenders.
What to watch: fourth-quarter operating cash flow in February, against the $11.8 million of last year's fourth quarter. A figure above $61 million would complete the year's plan and show the third quarter was not a one-time collection.
Refinancing Pushes Debt Deadlines Out Past 2028
Most of Integra's borrowings were due in 2028. The cap on its leverage was set to tighten to 4.0 times earnings next year, and the ratio stood at 4.1 in June, so this was the one risk that did not depend on how the products sold. On October 19 the company closed a $2.1 billion refinancing that it says "extended debt maturities and enhanced financial flexibility".
- Bank facility: $1.65 billion, made up of a $600 million term loan A, a $600 million revolver and a $450 million term loan B
- Notes: $450 million of senior secured notes at 9.5%, due 2033
- Leverage cap: 4.50 times earnings for the fourth quarter, then 4.25 during 2027, instead of the 4.0 it faced before
- Interest rate: up by 1–2 percentage points, "near the high end" of that range
This matters because the deadline is gone and the cap is looser, so the balance sheet no longer sets the company's timetable. The price is a higher interest bill, roughly $9 million a quarter at the top of the range by our math, which the fourth-quarter profit outlook already includes.
What to watch: net interest expense in the fourth quarter, the first with the new debt in place. A rise much above that figure would mean the refinancing cost more than management said.
🐻 Bear Case
Sales Will Fall in the Fourth Quarter
In July the plan had revenue rising through the second half on seasonality and better supply, with growth before currency of about 2% for the year at the middle of the range. Now Integra expects fourth-quarter revenue of $413–433 million, down 5.2% to 0.5% from a year ago, the first decline since last year's fourth quarter.
Two things changed. The flooded Cincinnati plant will cost $15–20 million of fourth-quarter sales, mostly in Neurosurgery, and will not run fully again until the second quarter of 2027. Chairman and chief executive Stuart Essig also lowered the Tissue Reconstruction outlook after "softer-than-expected results" there, citing "more measured expectations for portions of our Tissue Reconstruction business".
- Full-year revenue: $1.634–1.654 billion, cut $30.5 million at the middle since July
- Full-year growth before currency: −0.3% to 0.9%, from 0.8% to 3.3%
- Fourth-quarter cut against what July implied: about $23 million, of which about $6 million is not the flood, by our math
- Specialty Surgery outside Cincinnati: outlook unchanged from July, the company said
This matters because the flood ends, but the Tissue Reconstruction weakness is not tied to it, and even without the flood the fourth quarter would grow only about 1% by our math. The acceleration the company counted on has not come: third-quarter growth before currency was 2.5%, at the low end of the 1.9–5.7% range set in July.
What to watch: Tissue Reconstruction revenue in the fourth quarter against the $107 million printed this quarter. A further decline with SurgiMend shipping would mean the weakness is in the products, not the plant.
Profit Rose on Other Income While Margins Fell
Integra entered the year promising wider margins excluding one-offs: gross margin up 0.6 percentage points and EBITDA margin, operating profit before depreciation, up 1 point. This quarter the presentation says profit per share was "Supported by strong cost management".
The margins went the other way. Gross margin excluding one-offs fell to 61.1% from 62.9%, because the cost of making the products rose 1.8 percentage points of revenue. Lower selling and administrative costs offset most of that, so the EBITDA margin was close to flat.
- Selling and administrative costs, excluding one-offs: 39.2% of revenue, down 2.3 points
- EBITDA margin, excluding one-offs: 19.4%, down 0.1 point; EBITDA itself up 1.7%
- Other income, excluding one-offs: $5.5 million, against a $0.8 million expense a year ago
- Profit per share, excluding one-offs: $0.59, up 9%
This matters because almost all of the profit growth came from below the operating line. By our math adjusted pre-tax profit rose $8.3 million, and $6.4 million of that was the swing in other income, which the release does not explain. For the full year the company now expects both margins flat with 2025, because its savings were "offset by unfavorable mix and Cincinnati impacts", and it says the insurance that supports the profit outlook sits in other income, outside EBITDA.
What to watch: other income and the EBITDA margin in the fourth quarter, read separately. Profit per share inside the $0.61–0.71 range on insurance alone would mean the operating business earned less than the headline shows.
Wound Products Keep Shrinking Before SurgiMend Returns
Tissue Reconstruction, the division that sells skin and tissue repair products such as Integra Skin, DuraSorb and PriMatrix, is 30% of Integra's revenue. The company still lists "the relaunch of SurgiMend in the fourth quarter of 2026" among its plans, and the division's recovery rests on products like that coming back.
This quarter Wound Reconstruction fell 2.9%, the second straight decline, because growth in DuraSorb and the relaunched PriMatrix was offset by declines in MicroMatrix and Integra Skin; the presentation points to a "slower Integra Skin recovery". The company also renamed its Private Label business Corporate Partnerships, "a name that better reflects the nature of these customer relationships".
- Wound Reconstruction Solutions: −2.9%, after −4.1% last quarter
- Corporate Partnerships: +0.2%, in line with the company's plan for the quarter
- Tissue Reconstruction total: −2.2%, to $107.1 million; international sales down at a low double-digit rate
- ENT, in the other division: −1.1% on fewer sinus balloons
This matters because two relaunched products are already selling and the line is still below zero, so the returns so far replace lost sales rather than add to them. The company cut its fourth-quarter outlook for this division rather than count on SurgiMend, and the materials do not say how much of PriMatrix's old revenue has come back.
What to watch: Wound Reconstruction growth in the fourth quarter, the first with SurgiMend shipping. Another decline would mean the returning products are not enough to offset what Integra Skin and MicroMatrix are losing.
Risks This Quarter Didn't Answer
Five standing concerns received no new numbers in the release or the presentation, and one got only a partial answer; each has a disclosure that would move it.
- FDA warning letters: three remain open and gate SurgiMend's wider approval; the fourth-quarter report will say whether the 2024 action items are done as promised.
- MediHoney: still off the market with a 2027 return; no update.
- Relaunch recapture: no figure for how much of PriMatrix's or SurgiMend's old revenue has returned; any percentage would move the case either way.
- Fourth-quarter cash: the plan needs $61–71 million by our math, against $11.8 million a year ago; the quarter made it likelier but did not deliver it.
- Tariff refunds: the receivable recorded in the spring for tariffs already paid gets no update; collections would show in the quarterly filing.
- Securities litigation and the stayed derivative suits: no update; the quarterly filing's legal note will say.
👓 Other Themes
Tariffs Still Cost About 10 Cents a Share
Integra's outlook assumes Section 301 tariff rates for the rest of the year and a 14% tariff on its exports to China, for a full-year cost of about 10 cents of profit per share excluding one-offs, unchanged from July. The presentation reports an "Immaterial impact from FX in updated guidance", with the euro assumed at 1.15 dollars.
💲 Other KPIs
Fell $30 million since December while quarterly revenue held about flat. Receivables, the money customers owe for goods already shipped, are now 61% of a quarter's sales, from 64% at year-end and 68% in March. Faster collection is where a good part of the third-quarter cash came from, by our reading, and it cannot repeat every quarter.
Down 5.7% since December, after the company built stock through 2025 to restore safety levels. Inventory now equals 113% of a quarter's sales, back to where it stood at year-end from 126% in March. Part of the drop is the flood: $5.7 million of Cincinnati costs, including lost inventory, ran through cost of goods sold.
Up 2.2% from a year ago, with no buybacks to offset the new shares, and the count has risen every quarter this year. The extra shares took about a cent off profit per share excluding one-offs this quarter, by our math. The company assumes 77–78 million shares for the full year.
🔮 Guidance
Cut. The plan now has fourth-quarter sales falling 5.2% to 0.5% from a year ago, the first decline since last year's fourth quarter. The flood explains $15–20 million of it, and the lower Tissue Reconstruction outlook most of the rest, because the Specialty Surgery outlook outside Cincinnati is unchanged. Against this quarter, the middle of the range is up about $12 million, half the step-up management described in July.
New. At $0.66 in the middle, profit per share would fall 20% from a year ago. The range includes insurance for the sales Cincinnati could not ship, booked in other income, and the higher interest on the new debt. By our math the July plan had left $0.69–0.87 for this quarter, so the top of the new range barely reaches the bottom of the old one.
Cut, first on October 2 and confirmed today. The middle of the range fell $30.5 million, to about 0.5% growth for the year. Before currency, growth is now −0.3% to 0.9%, from 0.8% to 3.3% in July. The flood accounts for $22–27 million of the cut by our math, and Tissue Reconstruction for most of the rest. Moves this year: 0, −$7.5 million for currency, then −$30.5 million.
Cut by 10 cents at both ends, back to the range the company set in February before tariff relief lifted it in May. The middle, $2.35, is 5% above 2025. The first nine months produced $1.69, so the fourth-quarter range above is what remains. Moves by vintage: +10 cents, 0, −10 cents.
Unchanged since October 2, and at the lower side of the roughly $200 million that July's plan implied. The first nine months produced $128.6 million. By our math the fourth quarter therefore needs $61–71 million, against $11.8 million a year ago, a big step but less than the company has just produced in one quarter.
Cut. The company now expects gross margin excluding one-offs to stay at 2025's 61.9%, instead of rising 0.6 percentage points, because its savings were "offset by unfavorable mix and Cincinnati impacts". The first nine months ran at 62.1%. By our math the fourth quarter would then run near 61%, below the 61.7% of a year ago.
Cut from a 1-point margin rise to flat with 2025, when EBITDA excluding one-offs was $317 million. The company blames mix and the fact that insurance for Cincinnati's lost sales lands in other income, outside EBITDA. By our math that leaves about $83 million for the fourth quarter. That is a margin near 20%, against 24% a year ago.
❓ Key Questions
Does the 3.5 times leverage target still stand?
In July management said it expected to approach the upper end of its 2.5–3.5 times target range by year-end. The ratio is 3.8 and the new loan cap is 4.50; the release does not repeat the target.
What is the $5.5 million of other income?
Other income excluding one-offs swung from a small expense to $5.5 million and supplied most of the quarter's profit growth by our math. The release does not say what it is or whether it recurs.
How much of PriMatrix's old revenue has come back?
PriMatrix returned a year ago and SurgiMend follows this quarter. The recovery case rests on how much lost revenue these products recapture, and the materials give no percentage.
How much insurance is in the fourth-quarter profit outlook?
The $0.61–0.71 range includes business-interruption recoveries for lost Cincinnati sales, booked in other income. Without the amount and timing, readers cannot separate what the operating business earns from what the insurer pays.
What does the refinancing cost in fees and annual interest?
The company says its rate rises near the top of a 1–2 point range on about $1.8 billion of debt, up to $37 million a year by our math. The fees and the 2027 interest line are not given.